Replimune Group (NASDAQ:REPL) Issues Earnings Results

Replimune Group (NASDAQ:REPL) released its quarterly earnings data on Friday. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03), Zacks reports.

Replimune Group Price Performance

Shares of REPL traded down $0.22 on Friday, hitting $14.97. The company’s stock had a trading volume of 2,398,241 shares, compared to its average volume of 8,223,322. The company has a market capitalization of $1.26 billion, a PE ratio of -4.43 and a beta of 0.88. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $15.70. The company has a 50 day moving average price of $10.66 and a 200 day moving average price of $7.79. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 11,448 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the completion of the transaction, the chief financial officer owned 225,108 shares in the company, valued at approximately $2,919,650.76. The trade was a 4.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the transaction, the insider directly owned 224,215 shares in the company, valued at approximately $2,908,068.55. This represents a 4.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 81,868 shares of company stock worth $1,017,068. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in REPL. RTW Investments LP increased its position in Replimune Group by 11.6% in the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after acquiring an additional 744,620 shares in the last quarter. State Street Corp lifted its position in shares of Replimune Group by 26.3% during the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after purchasing an additional 768,982 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Replimune Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after purchasing an additional 9,707 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in shares of Replimune Group by 62.5% during the fourth quarter. Toronto Dominion Bank now owns 2,229,527 shares of the company’s stock valued at $21,671,000 after purchasing an additional 857,475 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: FDA approval creates a commercial opportunity: Replimune announced that TUDRIQEV™ (RP1) in combination with nivolumab received FDA accelerated approval for advanced melanoma. The company expects to launch the treatment within 60 days, potentially allowing it to begin generating commercial revenue and validating its oncolytic-immunotherapy platform. Replimune fiscal first-quarter 2027 results and corporate update
• Positive Sentiment: Financing supports the launch: A recently completed $150 million financing extends Replimune’s cash runway and is intended to fund the commercial rollout and confirmatory trial required under the accelerated-approval pathway. The added liquidity reduces near-term funding concerns, though the offering may dilute existing shareholders. Replimune corporate update
• Positive Sentiment: Commercial leadership added: Michelle DiNapoli was appointed chief commercial officer, strengthening the company’s preparations for its first product launch.
• Neutral Sentiment: Insider sales were attributed to taxes: The CEO, CFO, CAO and another insider sold shares totaling approximately $906,000. SEC filings indicate the transactions covered tax withholding tied to vested equity awards, and the executives retained significant holdings, limiting the negative signal.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Replimune reported a fiscal first-quarter loss of $0.72 per share versus the consensus estimate of a $0.69 loss. As a commercial-stage biotechnology company, it remains unprofitable and is expected to post a substantial full-year loss.
• Negative Sentiment: Securities litigation remains an overhang: Multiple law firms are promoting a class action covering investors who bought REPL shares from October 20, 2025, through April 10, 2026. The lawsuit alleges misleading statements about RP1 and FDA study-design issues; the allegations have not been proven. The lead-plaintiff deadline is October 5, 2026. Replimune securities lawsuit deadline alert

Analyst Ratings Changes

Several analysts recently commented on REPL shares. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on Replimune Group from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Friday, August 7th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. Finally, Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Moderate Buy” and a consensus target price of $11.86.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.